Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARKET: AMT-101 + Adalimumab in UC
NCT05372939Phase 2Completed
- Sponsor
- Applied Molecular Transport
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 4
01
Overview
A Phase 2 trial of AMT-101 in ulcerative colitis (UC), sponsored by Applied Molecular Transport. Started Feb 2021; status: completed.
02
Drugs
AMT-101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05372939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372939.